Meningioma is a frequently occurring tumor of the meninges surrounding the central nervous system. Loss of the short arm of chromosome 1 (1p) is the second most frequent chromosomal abnormality observed in these tumors. Previously, we identified a 3.7 megabase (Mb) region of consistent deletion on 1p33-p34 in a panel of 157 tumors. Loss of this region was associated with advanced disease and predictive for tumor relapse. In this report, a high-resolution integrated map of the region was constructed (CompView) to identify all markers in the smallest region of overlapping deletion (SRO). A regional somatic cell hybrid panel was used to more precisely localize those markers identified in CompView as within or overlapping the region. Additional deletion mapping using microsatellites localized to the region narrowed the SRO to approximately 2.8 Mb. The 88 markers remaining in the SRO were used to screen genomic databases to identify large-insert clones. Clones were assembled into a physical map of the region by PCR-based, sequencetagged site (STS) content mapping. A sequence from clones was used to validate STS content by electronic PCR and to identify transcripts. A minimal tiling path of 43 clones was constructed across the SRO. Sequence data from the most current sequence assembly were used for further validation. A total of 59 genes were ordered within the SRO. In all, 17 of these were selected as likely candidates based on annotation using Gene Ontology Consortium terms, including the MUTYH, PRDX1, FOXD2, FOXE3, PTCH2, and RAD54L genes. This annotation of a putative tumor suppressor locus provides a resource for further analysis of meningioma candidate genes.
Meningioma is a tumor of the arachnoid meninges surrounding the central nervous system. It accounts for 13-20% of adult brain tumors, with an overall incidence of approximately 7-8/100 000 per year, including asymptomatic cases discovered at autopsy (Nakasu et al., 1987; Bondy and Ligon, 1996) . Although usually benign, 5-10% of tumors are malignant and invasive and 20-40% of patients suffer from recurrent disease (Zu¨lch, 1979; Mathiesen et al., 1996) . Meningiomas are also associated with Neurofibromatosis type 2, occurring nearly as frequently in that disease as vestibular schwannomas (Evans et al., 1992) .
Molecular studies of meningiomas have identified frequent deletion of the long arm of chromosome 22 (22q) in 60-70% of tumors (Dumanski et al., 1987 (Dumanski et al., , 1990 Rempel et al., 1993; Ruttledge et al., 1994b) . Inactivation of the NF2 tumor suppressor gene has been demonstrated in approximately 60% of cases (Ruttledge et al., 1994a; Wellenreuther et al., 1995) . Several other genomic regions have been proposed to undergo alteration in meningiomas. Cytogenetic studies have shown that allelic loss of the short arm of chromosome 1 (1p) is the second most common karyotypic abnormality observed in these tumors (Jime´nez-Lara et al., 1992) . Loss of heterozygosity (LOH) of 1p has been suggested to play a role in tumor progression (Simon et al., 1995; Sulman et al., 1998; Leone et al., 1999; Muller et al., 1999; Lamszus et al., 2000) .
In order to systematically identify the frequency and extent of 1p LOH in meningioma, we previously examined a panel of 157 matched normal and tumor DNAs and characterized a region of consistent deletion within 1p33-p34 (Sulman et al., 1998) . This smallest region of overlapping deletion (SRO), flanked distally by microsatellite marker D1S271 and proximally by D1S2134, spans approximately 1.5 centiMorgans (cM) or 3.7 megabases (Mb). Allelic loss of this region correlated significantly with 22q deletion and NF2 inactivation and was associated with advanced disease (WHO grade III). Moreover, 1p LOH was predictive for tumor recurrence, suggesting that a putative tumor suppressor gene in this region may serve as a molecular marker for advanced disease. Several additional tumor types exhibit characteristic deletions of this region on 1p, including breast carcinoma and oligodendroglioma (Bieche et al., 1993; Bello et al., 1995a, b) . In addition to neoplasia, several genetic disorders demonstrate linkage to within a 2 cM region overlapping this region, including paroxysmal choreoathetosis, one form of hereditary congenital ptosis, and muscle-eye-brain disease, which was recently shown to involve mutation of the POMGNT1, located within the SRO (Auburger et al., 1996; Engle et al., 1997; Cormand et al., 1999; Yoshida et al., 2001 ).
In the current study, we have endeavored to fully characterize this tumor suppressor locus by conducting additional deletion mapping in the region and by precisely identifying and localizing transcripts to this region. These candidate genes can then be assessed for their role in tumorigenesis.
To identify all expressed genes in the SRO as well as additional polymorphic loci for deletion mapping, we first constructed a high-resolution map (CompView) of the region integrating all publicly available radiation hybrid (RH), genetic linkage (GL), and cytogenetic data for chromosome 1 (White et al., 1999b) . According to the CompView map, the SRO spans 57.7 centirays (cR) and approximately 3.7 Mb of physical distance. Analysis of the defined region yielded 114 unique loci within or overlapping the SRO, including 76 transcripts, 33 polymorphisms, and five anonymous markers. Another 14 genes were identified as mapping to 1p32-p34 by Medline queries (White et al., 1999a; Schutte et al., 2001) . For all markers, unique sequence-tagged sites (STSs) were selected or constructed for STS content mapping.
Since many of the 128 markers identified could not be precisely ordered within the SRO, a somatic cell hybrid panel containing a series of 1p deletions and translocations was screened to identify clones which could be used for marker localization (Roberts, 1991) . Two hybrids containing 1p chromosomal breakpoints were identified (Figure 1 ) that together roughly approximate the SRO: WAG8, which contains a (1;X) translocation, and 1108, which contains a 1p deletion. The breakpoint of the WAG8 1p translocation lies just distal to D1S2713 and the distal breakpoint of the 1108 deletion lies just proximal to D1S2824. Using this panel, 24 markers could be localized outside of the SRO, 13 distally and 11 proximally.
Of the remaining 29 polymorphic markers still mapping within the SRO following somatic cell hybrid analysis, seven had sufficient ordering information in CompView to be useful for LOH analysis. Three tumors, #79, #96, and #106, whose deletions were previously used to define the SRO, were subjected to further LOH analysis (Figure 1 ). The distal boundary of LOH for tumor #79 was further refined to proximal of D1S421, reducing the SRO by approximately 0.9-2.8 Mb. No further reduction was possible proximally. By moving the distal boundary of the SRO to D1S421, an additional 16 markers, including 12 genes, were excluded from the region.
The 88 markers still localized to the SRO as well as some flanking markers were used to screen the Sanger Institute's chromosome 1 physical mapping database to identify candidate P1-and bacterial-artificial chromosomes (PACs and BACs, respectively) in the region (Gazetteer 1998; Lander et al., 2001). In addition, clone fingerprint data both from the Sanger Institute and the Washington University Genome Sequencing Center were screened to identify additional clones (Pruitt, 1997) . Approximately 118 clones were identified in this manner and obtained for STS content mapping. Initially, six contigs were assembled within the region. As the clone sequence became available, conventional PCR-based STS content mapping was confirmed by a DNA sequence-based in silico STS identification algorithm (e-PCR, modified from Schuler, 1997). The (Sulman et al., 1998) . PCR was performed in the presence (for LOH analysis) or absence (for somatic cell hybrid analysis) of a [g 32 P]dATP endlabeled primer. Somatic cell hybrid DNAs were the generous gift of Dr John K Cowell (Roberts, 1996) . Microsatellite markers used for LOH analysis were analysed as described (Sulman et al., 1998) . Products from STSs used for somatic cell hybrid mapping were separated by gel electrophoresis (Visigel; Stratagene, La Jolla, CA, USA). All data generated were stored and analysed in a custom relational database developed using 4th Dimension (4D, Inc., San Jose, CA, USA). Shown at left is an ideogram of chromosome 1p. Adjacent to the ideogram is a portion of the genetic linkage map of chromosome 1, corresponding to bands p33-34 (Vance et al., 1997) . Centimorgan (cM) positions are shown for the markers on the genetic map. Microsatellites located between D1S2713 and D1S2824 have been ordered based on the CompView map and/or the physical map (Figure 2) . LOH results for the three tumors whose allelic deletions define the meningioma SRO are shown. An open circle indicates retention of heterozygosity, a filled circle indicates loss of heterozygosity, and a dash indicates constitutional homozygosity. A large bracket to the right of the LOH data identifies the meningioma SRO, spanning from D1S421 distally to D1S2134 proximally. Shown to the right of the LOH results are the somatic cell hybrids. The retention patterns of the hybrids are indicated by gray bars. WAG8 contains a (1;X) translocation with a proximal 1p breakpoint between D1S2713 and D1S1586. 1108 contains a deletion of distal 1p with a breakpoint between D1S2824 and D1S2661. At far right are ethidium bromide-stained gels demonstrating the retention pattern of the somatic cell hybrids for specific marker combination of e-PCR-based content mapping and clone sequence comparisons using BLAST (Altschul et al., 1990) permitted the closure of all the five gaps in the physical map. The resultant physical map consists of a single PAC and BAC clone contig containing a total of 106 clones. A minimal tiling path of this contig, represented by 43 clones, is shown in Figure 2 . Draft sequence for 30 and finished sequence for 45 of the 106 clones on the physical map is presently available.
The physical map was confirmed by comparison to the build 31 sequence assembly of the human genome from the National Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov/genome/guide/human/), using version 17 of the Human Genome Browser from the University of California, Santa Cruz (UCSC Genome Browser) (Kent et al., 2002) . An additional 15 genes, including 10 previously characterized, were identified within or just flanking the SRO by direct sequence analysis or by comparison to genome assemblies. In total, 59 genes have been localized to the SRO (Table 1) , including 32 genes previously characterized with respect to function. Of the remaining 27 genes, 11 represent putative full-length transcripts. The remaining 16 genes consist of clusters of expressed sequences or a single expressed sequence tag, the majority of which support gene predictions shown in the sequence assembly. The build 31 assembly consists of two sequence contigs reported by the NCBI as nonoverlapping (Genbank Accession numbers NT_004852 and NT_032977), but which in fact overlap significantly according to the analysis presented here (see Figure 2) .
To further identify likely candidates, the European Bioinformatics Institute's (EBI) annotation of the human proteome (Brooksbank et al., 2003; Pruess et al., 2003) was screened using the genes in the SRO. The EBI annotation relies on terms defined by the Gene Ontology (GO) Consortium that describe gene function and localization (Gene Ontology Consortium, 2001 ). To specifically identify tumor suppressor genes, two GO terms were queried against the entire EBI annotations (dated January 23, 2003 and available at www. geneontology.org): 'tumor suppressor' (GO:0008181) and 'negative regulation of cell proliferation' (GO: 0008285). A total of 236 genes ('the suppressor set') were identified in this manner. The set of molecular function and biological process GO terms for this set of genes as used to query the set of GO terms belonging to all the genes in the SRO. Of the 32 known genes in the SRO, 30 had GO annotations in the EBI dataset. Of these, 17 had annotations in common with the suppressor set. We propose this set of 17 genes as the most likely candidates.
Several of the genes within the SRO identified via the GO analysis are particularly compelling candidate tumor suppressors. The PTCH2 gene is a homolog to the Drosophila patched gene, whose product is involved in signaling with hedgehog in the establishment of segment polarity and anterior-posterior orientation (Smyth et al., 1999; Zaphiropoulos et al., 1999) . Mutations of the human PTCH gene, the first patched homolog identified, have been demonstrated in constitutional and tumor DNAs from patients with nevoid basal cell carcinoma syndrome (NBCCS). NBCCS is a developmental defect and tumor predisposition syndrome in which patients develop medulloblastomas and basal cell carcinomas (BCCs) as well as other tumors, including meningiomas (Hahn et al., 1996) . Analysis of PTCH2 in medulloblastomas and BCCs identified rare mutations of the gene (Smyth et al., 1999) . Mutational analysis in neuroblastoma failed to find evidence of PTCH2 mutations in the 14 tumors analysed (Jogi et al., 2000) . Nevertheless, no mutational studies of the gene have been conducted to date in meningioma.
There are several other plausible candidate genes in the region. The PRDX1 gene has been shown to be upregulated during cell proliferation (Prosperi et al., 1993 (Prosperi et al., , 1998 . The RAD54L gene is a member of a family of helicases (Rasio et al., 1997) . Genes with helicase activity have been implicated in a number of cancer predisposition syndromes (Bello et al., 2000) . However, mutational analysis of RAD54L in 25 oligodendrogliomas and 18 meningiomas failed to identify any deletions or inactivating mutations of the gene (Mendiola et al., 1999; Bello et al., 2000) . Specific variants in the MUTYH gene, involved in base excision repair, may play a role in cancer predisposition; however, somatic mutations of the gene have not been demonstrated in tumors (Al-Tassan et al., 2002) . In addition, microsatellite instability, as is seen in the defective mismatch repair of hereditary nonpolyposis colorectal cancer, is an infrequent finding in meningiomas (Pykett et al., 1994; Simon et al., 1996; Sulman et al., 1998) . The FOXD2 and FOXE3 genes belong to a family of genes with homology to Drosophila forkhead (Ernstsson et al., 1997; Blixt et al., 2000) . Members of the forkhead protein family have been shown to play a role in embryonic development and tumorigenesis (Galili et al., 1993; Li and Vogt, 1993; Shapiro et al., 1993; Downing et al., 1995) .
Several proposed 1p candidate meningioma suppressor genes have been mapped outside the SRO based on the work presented here. Santarius et al. (2000) conducted mutational analysis of the CDKN2C (p18
INK4C
) gene (located proximal to the SRO) in a panel of 40 meningiomas, identifying a single silent mutation in one tumor. Similarly, the alkaline phosphatase gene (ALPL) has been proposed as a candidate suppressor gene but maps quite distal to the SRO (Niedermayer et al., 1997) .
This annotation of the meningioma consensus deletion region will permit a focused interrogation of localized transcripts. While the large-scale efforts of the Human Genome Project will soon provide a finished sequence of the genome, focused analysis and validation of disease gene loci will still be necessary (Lander et al., 2001; McPherson et al., 2001; Venter, 2001) . In this report we provide a comprehensive ordering and identification of transcripts in the meningioma SRO, which is an important step towards the eventual elucidation of the meningioma 1p tumor suppressor gene. A complete evaluation of all candidate suppressor genes within the SRO will require a systematic Figure 2 Physical map of the meningioma SRO. STS content mapping for the construction of PAC and BAC contigs was accomplished initially by PCR amplification of clone DNAs using STSs in the region and then later confirmed using a program written in 4th Dimension (4D, Inc., San Jose, CA, USA) based on the e-PCR algorithm (Schuler, 1997) . Clones were prepared either in 5 or 500 ml cultures using the Qiagen Plasmid Midi Kit (Qiagen, Valencia, CA, USA) with modifications indicated by the manufacturer. To facilitate map closure, several STSs (those beginning with MG1P) were designed from an overlap sequence between clones by first screening the overlapping sequence using RepeatMasker (ftp.genome.washington.edu/cgi-bin/RepeatMasker) and then designing primers to the masked sequence using Primer3 (www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi). A linear order for all markers is shown from telomere (left) to centromere (right) at the top of the figure. The position of the meningioma SRO is indicated by a black bar. Underlined markers are microsatellites. Markers indicated with a w are anonymous STSs. All other markers are expressed transcripts. Markers with an * correspond to framework radiation hybrid markers on the CompView map (genome.chop.edu) whose linear order was predicted with high statistical probability. Below the marker list is a minimal tiling path of large-insert clones that span the region. Clone sizes are determined by the extent of STS content and do not reflect actual physical distance. Below the contig are the approximate positions of the NCBI sequence assemblies (build 31) for this region. Assemblies NT_004852 and NT_032977 overlap based on e-PCR results Annotation of the meningioma suppressor locus on 1p34 EP Sulman et al approach, including mutational analysis, transcriptional profiling, and functional demonstration of suppression.
